Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia

被引：24

作者：

Inami, SE ^{[1
]}

Okamatsu, K ^{[1
]}

Takano, M ^{[1
]}

Takagi, G ^{[1
]}

Sakai, S ^{[1
]}

Sano, J ^{[1
]}

Mizuno, K ^{[1
]}

机构：

[1] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Internal Med, Imba, Chiba 2701694, Japan

来源：

JAPANESE HEART JOURNAL | 2004年 / 45卷 / 06期

关键词：

statin; pleiotropic effect; oxidized low-density lipoprotein;

D O I：

10.1536/jhj.45.969

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, it has been reported that circulating oxidized low-density lipoprotein (OxLDL) might be a pivotal indicator for coronary artery disease and the severity of acute coronary syndromes. The purpose of this study was to investigate the effects of statins on Ox-LDL in patients with hypercholesterolemia. Sixteen patients with hypercholesterolemia were randomly assigned to 2 groups, one received 10 mg of pravastatin (n = 8) and the other received 20 mg of fluvastatin (11 = 8). The plasma level of Ox-LDL was measured using a newly developed sandwich enzyme-linked immunosorbent assay (ELISA) method. There were no differences between the two groups in Ox-LDL, total cholesterol (TC), or LDL cholesterol (LDL-C) at the baseline. The reduction in Ox-LDL in the fluvastatin group was significantly higher than that in the pravastatin group (47.5% versus 25.2%, P = 0.033). The reductions in TC and LDL-C did not differ between the two groups. Conclusion: The present study has shown for the first time that the level of circulating OxLDL was significantly decreased by treatment with statins. In addition, the lowering effect of statins on the circulating Ox-LDL was independent of their lipid-lowering effect. Fluvastatin was more effective than pravastatin with regard to decreasing the circulating Ox-LDL.

引用

页码：969 / 975

页数：7

共 21 条

[1] 7-BETA-HYDROPEROXYCHOLEST-5-EN-3-BETA-OL, A COMPONENT OF HUMAN ATHEROSCLEROTIC LESIONS, IS THE PRIMARY CYTOTOXIN OF OXIDIZED HUMAN LOW-DENSITY-LIPOPROTEIN [J].

CHISOLM, GM ;

MA, GP ;

IRWIN, KC ;

MARTIN, LL ;

GUNDERSON, KG ;

LINBERG, LF ;

MOREL, DW ;

DICORLETO, PE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11452-11456

[2]

Collins R, 2003, LANCET, V361, P2005

[3] Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes [J].

Ehara, S ;

Ueda, M ;

Naruko, T ;

Haze, K ;

Itoh, A ;

Otsuka, M ;

Komatsu, R ;

Matsuo, T ;

Itabe, H ;

Takano, T ;

Tsukamoto, Y ;

Yoshiyama, M ;

Takeuchi, K ;

Yoshikawa, J ;

Becker, AE .

CIRCULATION, 2001, 103 (15) :1955-1960

[4] Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study) [J].

Hulthe, J ;

Fagerberg, B .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1162-1167

[5] Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL [J].

Hussein, O ;

Schlezinger, S ;

Rosenblat, M ;

Keidar, S ;

Aviram, M .

ATHEROSCLEROSIS, 1997, 128 (01) :11-18

[6]

ITABE H, 1994, J BIOL CHEM, V269, P15274

[7] PROBUCOL PREVENTS THE PROGRESSION OF ATHEROSCLEROSIS IN WATANABE HERITABLE HYPERLIPIDEMIC RABBIT, AN ANIMAL-MODEL FOR FAMILIAL HYPERCHOLESTEROLEMIA [J].

KITA, T ;

NAGANO, Y ;

YOKODE, M ;

ISHII, K ;

KUME, N ;

OOSHIMA, A ;

YOSHIDA, H ;

KAWAI, C .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5928-5931

[8] Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody [J].

Kohno, H ;

Sueshige, N ;

Oguri, K ;

Izumidate, H ;

Masunari, T ;

Kawamura, M ;

Itabe, H ;

Takano, T ;

Hasegawa, A ;

Nagai, R .

CLINICAL BIOCHEMISTRY, 2000, 33 (04) :243-253

[9]

MOREL DW, 1983, J LIPID RES, V24, P1070

[10]

Nakamura T, 2000, CHEM PHARM BULL, V48, P235

← 1 2 3 →